|
|
| Saturday, February 7, 2009 |
| |
|
| 08:30-10:00 |
Session 10 |
| Hall A |
BLADDER CANCER:
NON-MUSCLE INVASIVE BLADDER TUMORS |
| Chairperson: |
M. Marberger, Austria |
| |
|
| Capsule: |
How can we improve diagnosis and treatment of non-muscle invasive bladder tumors?
|
|
08:30-08:45
08:45-09:00
09:00-09:15
09:15-09:30
09:30-09:45 |
Improving diagnosis
M. Burger, Germany
Grading, Staging, Prognosticators: To be understood by clinicians
E. Comperat, France
pTaG1: Follow-up and management of recurrent tumors
Y. Fradet, Canada
Update on topical therapy
F. Witjes, The Netherlands
High grade non-muscle invasive TCC: When is more evaluation / treatment needed?
M. Brausi, Italy
|
| |
|
| 09:45-10:00 |
Discussion
M. Marberger, Austria
|
| |
|
| 08:30-10:00 |
Session 11 |
| Hall B |
PROSTATE CANCER: LOCALLY ADVANCED |
| Chairpersons: |
F. Debruyne, The Netherlands
S. Egawa, Japan |
| |
|
| Capsule: |
Does surgery have a role in the treatment of locally advanced prostate cancer?
|
|
08:30-08:40
08:40-08:50 |
MRI of the prostate: Does it dictate treatment?
Yes: P. Mulders, The Netherlands
No: A. Alcaraz, Spain
|
| |
|
|
08:50-09:10
09:10-09:30 |
Debate: Locally advanced disease
Is there a role for surgery?
Yes: H. Huland, Germany
No: A. Sella, Israel
Extension of Lymph-node dissection
L. Boccon-Gibod, France
U. Studer, Switzerland
|
| |
|
|
09:30-09:45
09:45-10:00 |
Can we predict the outcome of treatment of locally advanced prostate cancer?
Z. Dotan, Israel
Surgery combined with hormones/radiation
L. Turkeri, Turkey
|
| |
|
| |
|
| 10:00-10:30 |
Coffee Break and Poster Viewing |
| |
|
| 10:30-11:30 |
Session 12 |
| Hall A |
PROSTATE CANCER: HRPC |
| Chairpersons: |
N. Fleshner, Candada
I. Sinescu, Romania |
| |
|
| Capsule: |
Have we improved outcomes for patients with HRPC in recent years?
|
| 10:30-10;45 |
Are Antagonists beneficial for HRPC patients?
P. Iversen, Denmark
F. Debruyne, The Netherlands
|
| |
|
|
10:45-11:10 |
Debate: Chemotherapy for HRPC
When should it be initiated?
For how long?
Is there an age limit?
Its role in an asymptomatic patient
Should hormonal treatment be continued?
Moderator: N. Fleshner, Canada
Panelists:
J. Fitzpatrick, Ireland
C. Sternberg, Italy
P. Iversen, Denmark
N. Mottet, France
|
| |
|
|
11:10-11:20
11:20-11:30 |
Debate: The Management of Chemotherapy failures
2nd Line Chemotherapy
J. Bellmunt, Spain
Novel treatment approaches
A. Sella, Israel
|
| |
|
| 10:30-11:30 |
Session 13 |
| Hall B |
UPPER TRACT UROTHELIAL CANCER |
| Chairpersons: |
P. Rischmann, France
M. Sosnowski, Poland |
|
|
| Capsule: |
Are we underutilizing minimally invasive approaches for Upper Tract TCC?
Is there a place for conservative surgical treatment?
|
|
10:30-10:40
10:40-10:50
10:50-11:10
|
Debate: Endoscopic treatment: Antegrade vs. retrograde
Antegrade: P. Geavlete, Romania
Retrograde: D. Tolley, UK
BCG/MMC irrigation of the upper tracts:
Pro: J. Palou, Spain
Con: A. Zlotta. Canada
|
| |
|
|
11:10-11:20
11:20-11:30 |
Debate: Segmental ureterectomy vs. Nephroureterectomy
Segmental ureterectomy: J. Irani, France
Nephroureterectomy: P. Geavlete, Romania
|
| |
|
| 11:30-13:00 |
Session 14 |
| Hall A |
TREATMENT STRATEGIES IN ADVANCED PROSTATE CANCER / GU MALIGNANCIES:
THE USE OF BISPHOSPHONATE ACROSS THE CONTINUUM |
| Chairperson: |
J. Fitzpatrick, Ireland |
| |
|
| Capsule: |
Are there new strategies in the approach of bone metastasis in prostate cancer?
|
|
Welcome & Introduction |
| |
|
|
Case-based presentation:
Are the extended benefits of Bisphosphonates Treatment worth the long-term treatment?
M. Colombel, France
C. Sternberg, Italy
F. Saad, Canada
A. Tubaro, Italy
|
| |
|
|
|
Is the prevention of Bone Metastasis possible in Prostate Cancer and GU Malignancies?
Pro: F. Saad, Canada
Con: A. Tubaro, Italy
|
| |
|
| |
Q&A & Closing |
| |
|
| 11:30-13:00 |
Session 15 |
| Hall B |
PRACTICAL TIPS IN MALE AND FEMALE INCONTINENCE |
| Chairpersons: |
F. Cruz, Portugal
D. Pushkar, Russia |
| |
|
| Capsule: |
Current approaches to surgical treatment of urinary incontinence: What else have we learned?
|
|
11:30-11:50
11:50-12:10
|
Female Incontinence
Pitfalls of TVT
M. Dambros, Brazil
Vaginal approach for Pelvic Organ Prolapse (POP): Tips and tricks
D. Pushkar, Russia
|
| |
|
|
12:10-12:30 |
Injectables for male and female Incontinence
What, when, where and how many?
D. Pushkar, Russia
|
| |
|
|
12:30-12:45
12:45-13:00 |
Male Incontinence
Failures with Artificial Urinary Sphincter
J. Heesakkers, The Netherlands
Male slings: Are they still there?
F. Cruz, Portugal
|
| |
|
| |
|
| 13:00-13:10 |
Best Abstract Award Ceremony |
| |
|
| 13:10-14:00 |
Lunch Break and Poster Viewing |
| |
|
| 14:00-15:30 |
Session 16 |
| Hall A |
BLADDER CANCER: INVASIVE DISEASE |
| Chairpersons: |
R. Hautmann, Germany
C. Llorente, Spain |
| |
|
| Capsule: |
Can we improve the results of radical cystectomy and bladder substitution?
|
|
14:00-14:15
14:15-14:30 |
Debate: Pathological assessment and clinical significance of prostatic involvement by TCC
Pathologist's view: E. Comperat, France
Urologist's view: C. Llorente, Spain
|
| |
|
|
14:30-14:40
14:40-14:50
14:50-15:00 |
Debate: Bladder substitution
How to obtain good results with orthotopic bladder substitution
H. Botto, France
R. Hautmann, Germany
U. Studer, Switzerland
|
| |
|
|
15:00-15:10
15:10-15:20
15:20-15:30 |
Debate: Cystectomy
Open to laparoscopic and robotic surgery: Why consider a change?
Open surgery: A. Stenzl, Germany
Laparoscopic surgery: F. Porpiglia, Italy
Robotic surgery: T. Piechaud, France
|
| |
|
| 14:00-15:30 |
Session 17 |
| Hall B |
TRICKS OF THE TRADE:
SURGERY FOR KIDNEY CANCER |
| Chairpersons: |
M. Marberger, Austria
A. Akdas, Turkey |
| |
|
| Capsule: |
What is left for open nephrectomy?
|
|
14:00-14:10
14:10-14:20 |
Debate: Open vs. laparoscopic radical nephrectomy
Open nephrectomy
O. Nativ, Israel
Laparoscopic nephrectomy
G. Guazzoni, Italy
|
| |
|
|
14:20-14:50 |
Debate: Laparoscopic nephrectomy in difficult situations: Is there a limit?
Obesity
Hilar and intrarenal tumors
Small lesion in the single kidney
Tumors over 7 cm in size
Locally advanced disease
Previous operations
Moderator: M. Marberger, Austria
Panel:
A. Finelli, Canada
G. Guazzoni, Italy
A. Nadu, Israel
|
| |
|
|
14:50-15:00
15:00-15:10
15:10-15:20
15:20-15:30
|
Debate: Partial nephrectomy
The significance of ischemia and positive margins
M. Marberger, Austria
Open vs. Laparoscopic vs. Robotic partial nephrectomy
Open: O. Nativ, Israel
Laparoscopic: A. Finelli, Canada
Robotic: A. Mottrie, Belgium |
| |
|
| |
|
| 15:30-16:30 |
Session 18 |
| Hall A |
MEET THE EXPERTS:
CASE DISCUSSION ON ADVANCED PROSTATE CANCER |
| Chairperson: |
J. Ramon, Israel
J. Bellmunt, Spain |
| |
|
| Capsule: |
Why so many options and limited consensus? Are the guidelines not useful or inappropriate?
|
|
PSA above 20 ng/ml at diagnosis
Locally advanced disease by MRI only
Clinically localized disease with PSA above 100 ng/ml
Failure of PSA to fall to undetectable following surgery
Pathological T3a with positive margins and undetectable PSA
Post radiotherapy and positive DRE
Gleason's 7 (3+4) pathology T3a, N1, negative margins and undetectable PSA
Panel
M. Brausi, Italy
S. Egawa, Japan
J. Fitzpatrick, Ireland
K. Miller, Germany
F. Rischmann, France
E. Solsona, Spain
|
| |
|
| 15:30-16:30 |
Session 19 |
| Hall B |
ENDO-UROLOGY AND NEPHROLITHIASIS |
| Chairpersons: |
D. Tolley, UK
P. Dinis, Portugal |
| |
|
| Capsule: |
Can we choose from so many opinions on how to treat ureteric stones and UPJ obstruction?
|
|
15:30-15:45
15:45-16:00
|
Debate: Ureteric stone
When to treat, how to treat?
Is there a place for medical treatment? When? Which treatment?
Moderator: D. Tolley, UK
M. Marberger, Germany
O. Traxer, France
|
| |
|
|
16:00-16:10
16:10-16:20
16:20-16:30 |
Debate: UPJ obstruction
Is endopyelotomy still indicated?
P. Geavlete, Romania
Laparoscopic pyeloplasty: Tricks of the trade
A. Nadu, Israel
Robotic pyeloplasty: Where we are?
A. Mottrie, Belgium
|
| |
|
| |
|
| 16:30-17:00 |
Coffee Break and Poster Viewing |
| |
|
| 17:00-18:30 |
Session 20 |
|
SATELLITE SYMPOSIUM:
ADVANCES IN THE THERAPY OF PROSTATE CANCER-INDUCED BONE DISEASE:
CURRENT INSIGHTS AND FUTURE PERSPECTIVES |
| Chairperson: |
K. Miller, Germany
|
|
Future perspectives in the management of prostate cancer-induced bone disease
B. Tombal, Belgium
RANKL inhibition in men with prostate cancer
A. Stenzl, Germany
Case presentation and discussion
K. Miller, Germany
|
|
|
|
| 17:00-18:30 |
Session 21 |
|
SATELLITE SYMPOSIUM:
PROSTATE CANCER - Fine-tuning hormonal therapy |
| Chairperson: |
L. Boccon-Gibod, France |
| |
|
|
How is hormone therapy prescribed in France?
The "CAPITAL" study
A. de la Taille, France
Non-controversial indications of hormone therapy: Metastatic and locally advanced cancer
P. Rischmann, France
The selective indications of hormone therapy: Clinically localized cancer, biological relapse after local treatment
N. Mottet, France
Hormonal therapy for prostate cancer: A holistic view
J. Irani, France
Hormone therapy: From guidelines to real-life clinical practice
P. Perrin, France
|
| |
|
| 18:30-19:00 |
CURy Happy Hour |
WebStudio.co.il